Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1405 | Enriched Survey Feedback Wiki | 1.00 |
| drug2845 | Peer Resilience Champion Wiki | 1.00 |
| drug967 | Colchicine Tablets Wiki | 0.50 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
COVID-19 is associated with a cytokine storm that leads to respiratory distress, multiorgan failure and elevated mortality. Oral colchicine exhibits high anti-inflammatory capacity attributed to the inhibition of microtubules polymerization, inflammasome and production of IL-1β and IL-6, which could prevent the inflammatory storm in COVID-19 patients at risk. We present a randomized clinical trial, controlled, open-label and pragmatic, including COVID-19 patients requiring hospitalization but no intensive care yet. Colchicine will be started within the first 48 hours and then administered for four weeks using a descending dose. The benefit will be study in terms of clinical evolution (WHO 7-point scale) and IL-6 levels, as well as other clinical and biochemical secondary end-points. In the case of positive results, the clinical impact would be relevant given that this oral medication is widely accessible which would help to prevent the inflammatory complications associated with COVID-19.
Description: improve in the clinical evolution of patients hospitalized
Measure: Changes in the patients' clinical status through the 7 points ordinal scale WHO R&D Blueprint expert group Time: 7,14,28 DaysDescription: improve in the clinical evolution of patients hospitalized
Measure: Changes in IL-6 concentrations Time: up to day 28.Description: time needed to reduce at least 2 points in the 7-point Ordinal Scale for Clinical Improvement by WHO R&D Blueprint expert group (0-7)
Measure: Improvement in the clinical status Time: up to day 28.Description: Sequential Organ Failure Assessment (SOFA score) (0-14)
Measure: Changes in the score for the Sequential Organ Failure Assessment (SOFA score) Time: up to day 28.Description: National Early Warning Score (NEWS scale
Measure: Changes in the punctuation in the National Early Warning Score Time: up to day 28.Description: C-reactive protein,
Measure: Changes in other inflammatory markers Time: up to day 28Description: TNF-alfa,
Measure: Changes in other inflammatory markers Time: up to day 28Description: GDF-15,
Measure: Changes in other inflammatory markers Time: up to day 28Description: IL-1β
Measure: Changes in other inflammatory markers Time: up to day 28Description: D-dimer
Measure: Changes in severity markers Time: up to day 28Description: leucocytes
Measure: Changes in severity markers Time: up to day 28Description: lymphocytes
Measure: Changes in severity markers Time: up to day 28Description: platelets
Measure: Changes in severity markers Time: up to day 28Description: LDH
Measure: Changes in severity markers Time: up to day 28Description: ferritin
Measure: Changes in severity markers Time: up to day 28Description: myocardial stress markers hsTnT
Measure: Changes in myocardial damage Time: up to day 28Description: myocardial stress markers NT-proBNP
Measure: Changes in myocardial damage Time: up to day 28Description: RT-PCR assay
Measure: Time until reaching a virus negative status Time: up to day 28Description: Length of hospital stay
Measure: Length of hospital stay Time: up to day 28Description: Number of days in the intensive care unit.
Measure: Number of days in the intensive care unit. Time: up to day 28Description: Mortality
Measure: Mortality Time: up to day 28Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports